

(2)

REPORT DOCUMENTATION PAGE

AD-A197 570

2b. DECLASSIFICATION/DOWNGRADING SCHEDULE			1b. RESTRICTIVE MARKINGS			
4. PERFORMING ORGANIZATION REPORT NUMBER(S)			3. DISTRIBUTION/AVAILABILITY OF REPORT Approved for public release; distribution unlimited.			
6a. NAME OF PERFORMING ORGANIZATION Univ. of Maryland at Baltimore			6b. OFFICE SYMBOL (if applicable)		7a. NAME OF MONITORING ORGANIZATION U. S. Army Research Office	
6c. ADDRESS (City, State, and ZIP Code) Dept. of Pharmacology and Toxicology, School of Pharmacy, Univ. of Maryland 20 N. Pine Street, Baltimore, MD 21201			7b. ADDRESS (City, State, and ZIP Code) P. O. Box 12211 Research Triangle Park, NC 27709-2211			
8a. NAME OF FUNDING/SPONSORING ORGANIZATION U. S. Army Research Office			8b. OFFICE SYMBOL (if applicable)		9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAA629-85-K-0123	
8c. ADDRESS (City, State, and ZIP Code) P. O. Box 12211 Research Triangle Park, NC 27709-2211			10. SOURCE OF FUNDING NUMBERS			
			PROGRAM ELEMENT NO.		PROJECT NO.	TASK NO.
					WORK UNIT ACCESSION NO.	
11. TITLE (Include Security Classification) Desensitization and Down-Regulation of Muscarinic Acetylcholine Receptors (Unclassified)						
12. PERSONAL AUTHOR(S) Dr. Esam E. El-Fakahany						
13a. TYPE OF REPORT Final		13b. TIME COVERED FROM 4/85 TO 4/88		14. DATE OF REPORT (Year, Month, Day) 6/22/88		15. PAGE COUNT 10
16. SUPPLEMENTARY NOTATION The view, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy, or decision, unless so designated by other documentation.						
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)			
FIELD	GROUP	SUB-GROUP				
19. ABSTRACT (Continue on reverse if necessary and identify by block number) Regulation of muscarinic acetylcholine receptor sensitivity and density was examined upon pre-exposure to muscarinic receptor agonists. Pretreatment of neuronal cells in culture resulted in a significant decrease in the response to subsequent exposure to agonists, in terms of cyclic GMP formation and the increase in phosphoinositide hydrolysis. This treatment also resulted in a decrease in the concentration of cell surface muscarinic receptors. This decrease in receptors was not accompanied by a change in receptor affinity for nonselective muscarinic receptor ligands. However, it resulted in a selective decrease in the relative densities of M_1 muscarinic receptors which have a high affinity for the selective antagonist pirenzepine. Activation of protein kinase C by phorbol esters also resulted in decreasing the responsiveness of muscarinic receptors. However, there was no change in receptor density. <i>Keywords: Muscarinic antagonists, Quinuclidinyl benzilate (QUB),</i>						
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT ☐ UNCLASSIFIED/UNLIMITED ☐ SAME AS RPT. ☐ DTIC USERS			21. ABSTRACT SECURITY CLASSIFICATION Unclassified			
22a. NAME OF RESPONSIBLE INDIVIDUAL			22b. TELEPHONE (Include Area Code)		22c. OFFICE SYMBOL	

DTIC
ELECTE
JUL 21 1988

ARO 21760-10-LS

El-Fakahany, Esam E.
S.S. # 468-92-3799

Desensitization and Down-Regulation of
Muscarinic Acetylcholine Receptors

FINAL REPORT

by

Esam E. El-Fakahany, Ph.D.

June 23, 1988

U.S. ARYM RESEARCH OFFICE

Contract #DAAG29-85-K-0123 (21760-LS)

University of Maryland at Baltimore

Approved for Public Release,
Distribution Unlimited

Accession For	
NTIS GRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	



Desensitization and Down-Regulation of
Muscarinic Acetylcholine Receptors

FINAL REPORT

by

Esam E. El-Fakahany, Ph.D.

June 23, 1988

U.S. ARMY RESEARCH OFFICE

Contract #DAAG29-85-K-0123 (21760-LS)

University of Maryland at Baltimore

Approved for Public Release,
Distribution Unlimited

Accession For	
NTIS GRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	



assay medium. For this purpose, complete saturation isotherms of [^3H]N-methylscopolamine were performed in control and desensitized cells (1 mM carbamylcholine, 30 min at 37°C), where it was found that preincubation with the agonist results in a 50% reduction in the B_{max} without any effect on the ligand affinity, ruling out the possibility of such an artifact.

To elucidate further that carbamylcholine-induced reduction in [^3H]N-methylscopolamine binding is a muscarinic receptor-mediated phenomenon, the effect of atropine on this process was studied. Pretreatment of cells with 10 nM atropine for 30 min at 37°C was found to retard subsequent carbamylcholine-induced desensitization drastically, as compared to naive cells not pretreated with the antagonist. On the other hand, atropine by itself did not cause any significant alterations in subsequent [^3H]N-methylscopolamine binding, suggesting that receptor activation is a necessary prerequisite for this phenomenon. In addition, agonist-induced reduction in [^3H]N-methylscopolamine binding took place only at temperatures above 20°C and increased with increasing the incubation temperature. The activation energy of the process was calculated to be 18 Kcal/mole, a value which is similar to that of desensitization of cyclic GMP formation in the same cells. Rapid and complete recovery of agonist-mediated receptor down-regulation took place within 30 min at 37°C, while no significant recovery occurred at 15°C.

In summary, cell surface muscarinic receptors in mouse neuroblastoma cells are subject to rapid regulation upon exposure to agonists. This phenomenon shares several characteristics with agonist-induced desensitization of cyclic GMP synthesis, including time course, dependence on agonist concentration, temperature sensitivity and reversibility. These observations suggest a possible implication of this regulation of surface receptors in desensitization of receptor function.

These studies of the regulation of muscarinic receptor density by exposure to agonists in mouse neuroblastoma cells were replicated in intact brain cell aggregates dissociated from adult rat brains. Initial experiments were concerned with a detailed investigation of the binding characteristics of [^3H]N-methylscopolamine in this system. It was found that the specific binding of 1 nM [^3H]N-methylscopolamine to muscarinic receptor increased linearly with increasing the amount of cell protein in the assay, up to 400 μg of protein. When the concentration of [^3H]N-methylscopolamine was varied over the range of 0.01 - 2 nM, the specific binding of the ligand was saturable, with very low level (< 5%) of nonspecific binding. Analysis of the saturation isotherms resulted in linear Scatchard plots with a B_{max} of 450 fmoles/mg protein and a K_D of 0.17 nM, suggesting that [^3H]N-methylscopolamine binds to a single homogeneous population of muscarinic receptors in rat brain cell aggregates, with no evidence of cooperativity, as indicated by a Hill coefficient of unity.

Displacement of the specific binding of 0.2 nM [^3H]N-methylscopolamine in intact brain cell aggregates by the muscarinic antagonists scopolamine, atropine or QNB resulted in steep displacement curves which could be analyzed sa-

tisfactorily according to a single binding site. On the other hand, the muscarinic agonists oxotremorine and carbamylcholine exhibited very shallow displacement curves which could be resolved into high- and low-affinity states by iterative nonlinear regression analysis.

These studies have suggested that dissociated adult rat brain cells may provide a useful and physiologically relevant model to study the regulation of muscarinic receptor binding, and probably function, in vitro. This technique offers an easy method to obtain intact differentiated brain cells with minimal diffusion barriers.

Preincubation of rat brain cell aggregates with carbamylcholine resulted in a time-dependent decrease in subsequent [3 H]N-methylscopolamine specific binding, an effect which reached a steady state in 3 hrs at 37°C. This effect of carbamylcholine was dependent on the concentration of the agonist in the incubation medium, with a half-maximal response occurring at 10 μ M. Similar to the findings in neuroblastoma cells, this agonist-induced down-regulation of [3 H]N-methylscopolamine binding was due to a reduction in the B_{max} with no significant change in the K_D . In addition, this phenomenon was absent when incubation with the agonist was performed at 15°C or in the presence of 100 nM atropine. Furthermore, the time course a disappearance of [3 H]N-methylscopolamine binding upon incubation with 1 mM carbamylcholine at 37°C was faster than that of [3 H]quinuclidinyl benzilate binding. These results suggested that desensitizing conditions are accompanied by a selective reduction in the concentration of surface muscarinic detected by [3 H]N-methylscopolamine. Another possible explanation is that these conditions transform the receptor into a conformation which can recognize [3 H]quinuclidinyl benzilate but not [3 H]N-methylscopolamine.

The effects of brief incubation with carbamylcholine on muscarinic receptor subtypes were investigated in mouse neuroblastoma cells (clone N1E-115). This treatment demonstrated that the muscarinic receptors in this neuronal clone can be divided into two types; one which is readily susceptible to regulation by receptor agonists, while the other is resistant in this regard. In control cells, both pirenzepine and carbamylcholine interacted with high- and low-affinity subsets of muscarinic receptors. Computer-assisted analysis of the competition between pirenzepine and carbamylcholine with [3 H]N-methylscopolamine showed that the receptor sites remaining upon desensitization are composed mainly of pirenzepine low-affinity and agonist high-affinity binding sites. Furthermore, there was an excellent correlation between the ability of various muscarinic receptor agonists to induce a decrease in consequent [3 H]N-methylscopolamine binding and their efficacy in stimulating cyclic GMP synthesis in these cells. Thus, only the agonists which are known to recognize the receptor's low-affinity conformation in order to elicit increases in cyclic GMP levels were capable of diminishing ligand binding. Taken together, these results suggest that the receptor population which is sensitive to regulation by agonists includes both the pirenzepine high-affinity and the agonist-low affinity receptor binding states. In addition, the sensitivity of these recep-

tor subsets to rapid regulation by agonists further implicates their involvement in desensitization of muscarinic receptor-mediated cyclic GMP formation.

Due to the selective decrease in the high-affinity sites of [3 H]N-methylscopolamine and [3 H]pirenzepine in neuroblastoma cells upon short-term desensitization, it was important to study the nature of the differences in binding of these two ligands and the binding of [3 H]quinuclidinyl benzilate to muscarinic receptors. These experiments were planned to help to explain why desensitization preferentially affects the binding of some muscarinic ligands but not others. Rat brain homogenates were used for this purpose due to the abundance of muscarinic receptors in this preparation relative to that in neuroblastoma cells.

The properties of the specific binding of the muscarinic receptor ligands [3 H]quinuclidinyl benzilate and [3 H]-methylscopolamine in rat brain were compared. The specific binding of both ligands was affected equally by heat, phospholipase A₂ and trypsin. [3 H]N-methylscopolamine labeled only a fraction of the total muscarinic receptors recognized by [3 H]quinuclidinyl benzilate in different brain areas and in the heart. Evidence has been found that [3 H]N-methylscopolamine, in fact, binds to a subpopulation of [3 H]quinuclidinyl benzilate binding sites. The distribution of the high-affinity binding sites of [3 H]N-methylscopolamine did not show a different tissue dependence as compared to the total receptor population, and did not parallel the distribution of the pirenzepine-sensitive M₁ receptor subtype. Similarly, the affinity of both [3 H]quinuclidinyl benzilate and [3 H]N-methylscopolamine varied from one tissue to another by a maximum of two fold. Although (-)-quinuclidinyl benzilate competed for the specific binding of [3 H]quinuclidinyl benzilate in different tissues according to the law of mass-action, N-methylscopolamine showed an anomalous interaction with two binding sites. The low-affinity binding sites of N-methylscopolamine showed saturability of [3 H]quinuclidinyl benzilate binding and stereoselectivity. When the binding characteristics of these N-methylscopolamine-inaccessible binding sites of [3 H]quinuclidinyl benzilate in the brain were investigated further, it was found that N-methylscopolamine bound exclusively with a single low affinity, while pirenzepine still interacted with two receptor populations incorporated in these sites. It is concluded from several lines of evidence that the heterogeneity of binding of N-methylscopolamine to muscarinic receptors does not represent an interaction with the muscarinic M₁ and M₂ receptor subtypes defined by pirenzepine. Thus, the unique binding profile of pirenzepine to muscarinic receptors cannot be explained merely on the basis of its hydrophilic nature.

We also studied the details of the interaction of the nonclassical muscarinic receptor antagonist pirenzepine with [3 H]quinuclidinyl benzilate binding sites in rat brain homogenates. Pirenzepine showed biphasic competition curves with a Hill coefficient lower than unity, and these curves were better described according to a two-site receptor model. The affinities and the relative preponderance of these sites were constant at different ligand concentrations, in accordance with a competitive type of interaction. Similar-

ly, pirenzepine did not influence the rate of dissociation of the [3 H]quinuclidinyl benzilate-receptor complex even at relatively high concentrations. However, although low concentrations of pirenzepine decreased the affinity of [3 H]quinuclidinyl benzilate for the receptor without affecting the density of the binding sites, higher concentrations of the antagonist decreased the receptor number in a reversible fashion. Schild plots of these data indicated an apparent deviation from simple competition in this experimental design, an observation which can be attributed to the selectivity of pirenzepine for different receptor subtypes. Furthermore, pirenzepine, at concentrations high enough to saturate both its high and low-affinity sites protected [3 H]quinuclidinyl benzilate binding sites in the brain against irreversible alkylation by propylbenzilylcholine mustard. Therefore, these data support a competitive nature of interaction of pirenzepine with brain muscarinic receptors.

Muscarinic receptors in mouse neuroblastoma N1E-115 cells, and in other tissues, mediated an increase in phosphoinositide hydrolysis. Diacylglycerol is one of the important products of this reaction, and it has been proposed to be the endogenous activator of protein Kinase C. Due to the involvement of protein Kinase C in the regulation of several neurotransmitter receptors, we investigated the effects of activation of this Kinase by phorbol esters on the sensitivity of muscarinic receptors in mouse neuroblastoma cells. Incubation of cells with phorbol-12-myristate-13-acetate (PMA) resulted in a time and concentration-dependent decrease in muscarinic receptor-mediated cyclic GMP synthesis. On the other hand, PMA had no effect on cyclic GMP formation induced by direct activation of guanylate cyclase by sodium azide. Although PMA did not compete directly for muscarinic receptors, nor did it decrease [3 H]N-methylscopolamine binding under conditions required to suppress cyclic GMP responses, PMA treatment resulted in the loss of pirenzepine high-affinity sites.

Publications

A. Manuscripts and Book Chapters:

1. Feigenbaum, P. and E. El-Fakahany: Regulation of Muscarinic Cholinergic Receptor Density in Neuroblastoma Cells by Brief Exposure to Agonist; Possible Involvement in Desensitization of Receptor Function. *Journal Pharmacology and Experimental Therapeutics*, 233, 134-140, 1985.
2. Lee, J. H. and E. El-Fakahany: Anomalous Binding of [³H]N-Methylscopolamine to Rat Brain Muscarinic Receptors. *European Journal of Pharmacology*, 110, 263-266, 1985.
3. Lee, J. H. and E. El-Fakahany: Use of Intact Rat Brain Cells as a Model to Study Regulation of Muscarinic Acetylcholine Receptors. *Life Sciences*, 37, 515-521, 1985.
4. Lai, W. S. V. Ramkumar and E. El-Fakahany: Possible Allosteric Interaction of 4-Aminopyridine with Rat Brain Muscarinic Acetylcholine Receptors. *Journal of Neurochemistry*, 44, 1936-1942, 1985.
5. Lee, J. H. and E. El-Fakahany: Heterogeneity of Binding of Muscarinic Receptor Antagonists in Rat Brain Homogenates. *Journal of Pharmacology Experimental Therapeutics*, 233, 707-714, 1985.
6. Lee, J. H. and E. El-Fakahany: [³H]N-Methylscopolamine Binding to Muscarinic Receptors in Intact Adult Rat Brain Cell Aggregates. *Biochemical Pharmacology*, 34, 4299-4303, 1985.
7. El-Fakahany, E.: Additional Complexities in the Binding of Muscarinic Receptor Antagonists, *Trends in Pharmacological Sciences*, 6, 430-431, 1985.
8. El-Fakahany, E.: V. Ramkumar and W. S. Lai: Multiple Binding Affinities of N-Methylscopolamine to Brain Muscarinic Acetylcholine Receptors; Differentiation from M₁ and M₂ Receptor Subtypes. *Journal of Pharmacology and Experimental Therapeutics*, 238, 554-563, 1986.
9. El-Fakahany, E.: C. L. Cioffi, M. M. Abdellatif and M. M. Miller: Competitive Interaction of Pirenzepine with Rat Brain Muscarinic Acetylcholine Receptors. *European Journal of Pharmacology*, 131, 237-247, 1986.
10. El-Fakahany, E. and J. -H. Lee: Agonist-Induced Muscarinic Acetylcholine Receptor Down-Regulation in Intact Rat Brain Cells. *European Journal of Pharmacology*, 132, 21-30, 1986.

11. Cioffi, C. L. and E. El-Fakahany. Short-Term Desensitization of Muscarinic Cholinergic Receptors in Mouse Neuroblastoma Cells; Selective Loss of Agonist Low-Affinity and Pirenzepine High-Affinity Binding Sites. *Journal of Pharmacology and Experimental Therapeutics*, 238, 916-923, 1986.
12. Cioffi, C. L. and E. El-Fakahany: Decreased Binding of the Muscarinic Antagonist [3 H]N-Methylscopolamine in Mouse Brain Following Acute Treatment with an Organophosphate. *European Journal of Pharmacology*, 132, 147-154, 1986.
13. Lai, W. S. and E. El-Fakahany: A Selective Effect of Protein Kinase C Activation on Pirenzepine High-Affinity Muscarinic Receptors in a Neuronal Clone. *European Journal of Pharmacology*, 129, 201-202, 1986.
14. Lee, N. H., V. Ramkumar and E. El-Fakahany: Charge But Not Chemical Class Explains the Selective Binding of [3 H]N-Methylscopolamine to a Sub-population of [3 H]Quinuclidinyl Benzilate Binding Sites in Rat Cerebral Cortex. *European Journal of Pharmacology*, 130, 153-155, 1986.
15. Lai, W. S. and E. El-Fakahany: Phorbol Ester-Induced Inhibition of Cyclic GMP Formation by Muscarinic Receptors in Murine Neuroblastoma Cells. *Journal of Pharmacology and Experimental Therapeutics*, 241, 366-373, 1987.
16. Lai, W. S. and E. El-Fakahany: Regulation of [3 H]Phorbol-12,13-Dibutyrate Binding Sites in Mouse Neuroblastoma Cells: Simultaneous Down-Regulation by Phorbol Esters and Desensitization of Their Inhibition of Muscarinic Receptor Function. *Journal of Pharmacology and Experimental Therapeutics*, 244, 41-50, 1988.
17. El-Fakahany, E. E.: Intact Cells; a Model for Studying Receptor Binding and Function: In "Receptor Pharmacology and Function", edited by M. Williams, R. A. Glennon and P. Timmermans, Marcel Dekker, New York, in press.
18. El-Fakahany, E. E., B. E. Alger, W. S. Lai, T. A. Pitler, P. F. Worley and J. M. Baraban: Neuronal Muscarinic Responses; Role of Protein Kinase C. *FASEB J.*, in press.
19. Lee, N. H. and E. E. El-Fakahany: Influence of Ligand Choice on the Apparent Binding Profile of Gallamine to Cardiac Muscarinic Receptors; Identification of Three Main Types of Gallamine-Muscarinic Receptor Interactions. *J. Pharmacol. Exp. Ther.*, in press.

20. Cioffi, C. L. and E. E. El-Fakahany: Lack of Alterations of Muscarinic Receptor Subtypes and Phosphoinositide Hydrolysis Upon Acute Treatment with the Organophosphate Disopropylfluorophosphate. Eur. J. Pharmacol., in press.

B. Abstracts:

1. Lai, W. S. and El-Fakahany, E.: Inhibition of Muscarinic Receptor-Mediated Cyclic GMP Formation by Phorbol Esters in Mouse Neuroblastoma Cells. Society for Neuroscience, 12, 901, 1986.
2. Cioffi, C. L. and El-Fakahany, E.: Differential Alterations of Cholinergic Muscarinic Receptors in Mouse Brain Resulting from Acute Di-isopropylfluorophosphate Treatment. Society for Neuroscience, 12, 307, 1986.
3. Cioffi, C. L. and El-Fakahany, E.: Selective Changes in Muscarinic Cholinergic Receptors Upon Short-Term Desensitization. The Pharmacologist, 28(3), Abstract 773, 237, 1986.
4. Lai, W. S. and El-Fakahany, E.: Phorbol Ester-Induced Changes in Muscarinic Receptor Conformations. The Pharmacologist, 28(3), Abstract 362, 158, 1986.
5. El-Fakahany, E., Ramkumar, V. and Lai, W. S.: Multiple Binding Affinities of N-Methylscopolamine to Brain Muscarinic Acetylcholine Receptors; Differentiation from M₁ and M₂ Receptor Subtypes. The Pharmacologist, 28(3), Abstract 359, 157, 1986.
6. Lai, W. S. and El-Fakahany, E.: Phorbol Ester Binding in Mouse Neuroblastoma N1E-115 cells. Federations Proceedings, 46, 1465, 1987.
7. Lee, N. H., Ramkumar, V. and El-Fakahany, E.: Comparison of [³H]N-methylscopolamine, [³H]Methylquinuclidinyl Benzilate and [³H]Quinuclidinyl Benzilate Binding in Rat Tissue Homogenates. Federation Proceedings, 46, 391, 1987.
8. Surichamorn, W., Lai, W. S. and El-Fakahany, E.: Effects of Aging on Brain Muscarinic Receptors. Federation Proceedings, 46, 1464, 1987.
9. Reeves, V. B. and El-Fakahany, E.: Comparison of the Tissue-Dependent Antimuscarinic Effects of Gallamine and Phencyclidine. Federation Proceedings 46, 392, 1987.
10. Lai, W. S. and El-Fakahany, E.: Sodium Fluoride Induces Cyclic GMP Formation In Mouse Neuroblastoma N1E-115 Cells. Society for Neuroscience, 13, 900, 1987.

El-Fakahany, Esam E.
S.S. # 468-92-3799

11. Surichamorn, W., Noronha-Blob, L. and El-Fakahany, E.: Increases in Phosphoinositide Hydrolysis, Intracellular Calcium and Cyclic GMP Formation by Phospholipase C. Society for Neuroscience, 13,900, 1987.
12. Cioffi, C. L. and El-Fakahany, E.: Down-Regulation of Muscarinic Cholinergic Receptors Following Short-Term Treatment in Mouse Neuroblastoma Cells in Suspension. Society for Neuroscience, 13,727, 1987.
13. El-Fakahany, E.: Agonist-Induced of Muscarinic Receptors in Nervous Tissue. Army Research Office Neuroscience Workshop, 1987.
14. Forray, C., C. L. Amrhein, O. N. Kim and E. E. El-Fakahany: Selective Antagonists Reveal Heterogeneity of Rat Brain Muscarinic Receptors that Mediate Inositol Phosphate Metabolism. Soc. Neurosci., in press.
15. Amrhein, C. L., W. Surichamorn and E. E. El-Fakahany: Glandular M₂ Muscarinic Receptors Mediate Inhibition of Cyclic AMP Formation. Soc. Neurosci., in press.
16. Surichamorn, W., C. Forray and E. E. El-Fakahany: Role Phosphoinositide Metabolism, Calcium and Arachidonate in Cyclic GMP Synthesis in N1E-115 Cells. Soc. Neurosci., in press.
17. Lee, N. H. and E. E. El-Fakahany; Gallamine Allosterically Modulates Muscarinic Receptor Binding and Antagonizes Phosphoinositide and Cyclic AMP Responses in N1E-115 Neuroblastoma Cells. Soc. Neurosci., in press.
18. Fryer, A. D., N. H. Lee and E. E. El-Fakahany: Effect of Methoctramine on Muscarinic Receptors in Murine Neuroblastoma Cells. Soc. Neurosci., in press.
19. Lai, W. S. and E. E. El-Fakahany: Evidence Against the Involvement of Protein Kinase C in Agonist-Induced Desensitization of Muscarinic Receptors. Soc. Neurosci., in press.
20. Surichamorn, W., C. L. Amrhein, M. McKinney, E. Richelson, S. Stenstrom, C. L. Cioffi and E. E. El-Fakahany: Anomalous Pirenzepine-Induced Antagonism of Muscarinic Responses. ASPET, in press.

List of Participating Scientific Personnel:

Esam E. El-Fakahany, Ph.D.

Catherine L. Cioffi, Ph.D.